Disease · MONDO_0020560
atypical teratoid rhabdoid tumor
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. atypical teratoid rhabdoid tumor. Diseases, record MONDO_0020560. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020560
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
AT/RT, ATRT, ATT/RHT, CNS rhabdoid neoplasm, CNS rhabdoid tumor, CNS rhabdoid tumour, atypical teratoid/rhabdoid tumor (WHO grade IV), atypical teratoid/rhabdoid tumor (morphologic abnormality), atypical teratoid/rhabdoid tumour (WHO grade IV), atypical teratoid/rhabdoid tumour (morphologic abnormality), central nervous system rhabdoid neoplasm, central nervous system rhabdoid tumor, central nervous system rhabdoid tumour, malignant brain rhabdoid neoplasm, malignant brain rhabdoid tumor, malignant brain rhabdoid tumour, malignant rhabdoid neoplasm of brain, malignant rhabdoid neoplasm of the brain, malignant rhabdoid tumor of brain, malignant rhabdoid tumor of the brain, malignant rhabdoid tumour of brain, malignant rhabdoid tumour of the brain, primary malignant brain rhabdoid neoplasm, primary malignant brain rhabdoid tumor, primary malignant brain rhabdoid tumour, primary malignant rhabdoid neoplasm of brain, primary malignant rhabdoid neoplasm of the brain, primary malignant rhabdoid tumor of brain, primary malignant rhabdoid tumor of the brain, primary malignant rhabdoid tumour of brain, primary malignant rhabdoid tumour of the brain, rhabdoid neoplasm of CNS, rhabdoid neoplasm of central nervous system, rhabdoid neoplasm of the CNS, rhabdoid neoplasm of the central nervous system, rhabdoid tumor of CNS, rhabdoid tumor of central nervous system, rhabdoid tumor of the CNS, rhabdoid tumor of the central nervous system, rhabdoid tumour of CNS, rhabdoid tumour of central nervous system, rhabdoid tumour of the central nervous system
- Open Targets
Drugs37
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| FILGRASTIM | CHEMBL1201567 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| THIOTEPA | CHEMBL671 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAZEMETOSTAT | CHEMBL3414621 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 37
See all 37 drugsTargets161
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HDAC1 | Histone deacetylase | 2 | Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3065 | Drugs and targets |
| HDAC2 | Histone deacetylase | 2 | Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3066 | Drugs and targets |
| HDAC3 | Histone deacetylase | 2 | Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/8841 | Drugs and targets |
| HDAC6 | Histone deacetylase | 2 | Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/10013 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5424 | Drugs and targets |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/5425 | Drugs and targets |
| POLD3 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/10714 | Drugs and targets |
| POLD4 | DNA polymerase (alpha/delta/epsilon) | 2 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 2 | https://conductscience.org/library/genes/57804 | Drugs and targets |
1 to 10 of 161
See all 161 targetsTrials21
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00085202 | Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor | Phase 3 | 416 | 2014-02-27 | Brain and Central Nervous System Tumors | CISPLATIN, CYCLOPHOSPHAMIDE, FILGRASTIM, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Phase 2 | 267 | 2025-03-11 | Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation | DOXORUBICIN, TAZEMETOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02601937 | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | Phase 1 | 109 | 2024-10-03 | Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary | TAZEMETOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00084838 | Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT | Phase 2 | 25 | 2015-12-24 | Central Nervous System Tumor, Pediatric | CISPLATIN, CYCLOPHOSPHAMIDE, CYTARABINE, DACTINOMYCIN, DOXORUBICIN, ETOPOSIDE, FILGRASTIM, HYDROCORTISONE, LEUCOVORIN CALCIUM, METHOTREXATE, TEMOZOLOMIDE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00003469 | Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System | Phase 2 | 4 | 2017-03-07 | Rhabdoid Neoplasm of CNS | ANTINEOPLASTON A10 | Its record names the disease | ClinicalTrials.gov |
| NCT01356290 | Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors | Phase 2 | 232 | Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent | BEVACIZUMAB, CELECOXIB, CYCLOPHOSPHAMIDE, CYTARABINE, ETOPOSIDE, FENOFIBRATE, THALIDOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT02114229 | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors | Phase 2 | 125 | Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor | ALISERTIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00392886 | Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors | Phase 3 | 120 | Brain and Central Nervous System Tumors | CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, METHOTREXATE, TEMOZOLOMIDE, THIOTEPA, VINCRISTINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | Phase 1/2 | 91 | CNS Tumor, Solid Tumor | ENTINOSTAT, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00217412 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | Phase 1 | 60 | Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific | ISOTRETINOIN, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 21
See all 21 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Average-Risk Group vs High-Risk Group: serious adverse events | 17 of 269 | 17 of 144 | 413 | NCT00085202 |
Source Trial comparisons
Papers from its trials15
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020560
GET https://conductscience.org/api/diseases/v1/MONDO_0020560/drugs?page=2